Informations générales (source: ClinicalTrials.gov)
Prevention and Pharmacological Management of Cardiac Adverse Drug Reactions Induced by Drugs Used in Oncology. The PICARO Cohort (PICARO)
Observational [Patient Registry]
University Hospital, Caen (Voir sur ClinicalTrials)
février 2019
janvier 2021
29 juin 2024
Recently, the medical management of cancer patients has considerably improved the
prognosis of these patients and today some cancers are becoming "chronic diseases". As a
result, new adverse effects (AEs) are observed, particularly cardiac.
These "new" cardiac AEs are the consequence of a significant increase in patients life
expectancy (delayed AEs not previously seen) but also the use of new pharmacological
classes of anticancer drugs such as kinase inhibitors. The incidence of these cardiac AEs
varies according to the patient profile and the anticancer molecules used, but their
impact on the morbidity and mortality of the patients is significant.
In this context, we started at the University Hospital of Caen Normandy in September 2017
a cardio-oncology program entitled "prevention and pharmacological management of cardiac
adverse effects induced by drugs used in Oncology" (PICARO program). This program
involves the pharmacology department (opening of a dedicated consultation), the
cardiology department (opening of a dedicated ultrasound consultation), vascular medicine
departement (opening of a dedicated consultation) and the oncology federation. This
program aims to be regional in the future. We therefore propose to build a cohort backed
up to the PICARO program to assess the regional impact of cardiac AEs of anticancer drugs
and thus to be better able to specify the number of AEs, the incidence and regional
prevalence of these drugs. .
The constitution of this cohort is only the first step towards the constitution in the
near future (2 years) of an observatory and then a regional registry of cardiac AEs
induced by anticancer drugs. The objectives associated with the establishment of such a
registry would be to reduce the number of cardiac AEs, the hospitalizations caused by
these AEs, a better information of health professionals and patients, an improvement in
the screening of patients at risk, all coming back in the context of health, clinical,
epidemiological and pharmacological surveillance.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU Caen - 14000 - Caen - Normandy - France | Joachim Alexandre, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient ≥ 18 years,
- Attents of cancer,
- Addressed for the first time to one of the PICARO program consultations at the
University Hospital of Caen Normandy,
- Written informed consent,
- Patient beneficiary of the french social insurance.
- Patient ≥ 18 years,
- Attents of cancer,
- Addressed for the first time to one of the PICARO program consultations at the
University Hospital of Caen Normandy,
- Written informed consent,
- Patient beneficiary of the french social insurance.
- Minor and major protected patients
- pregnant or nursing women
- patient already included in the PICARO cohort
- Patients under guardianship, curatorship, safeguard of justice or legal protection.